NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER Russian patent published in 2021 - IPC C12N5/784 A61P35/00 C12N15/00 

FIELD: biotechnology.

SUBSTANCE: claimed is a modified NK cell for immunotherapy of a PSMA-positive tumour, containing: a) a chimeric antigen receptor (CAR) on the surface of a cell, containing an antigen-binding domain binding to a tumour-associated marker PSMA, a hinge domain, a transmembrane domain, and an intracellular signalling domain capable of activating the NK cell; and b) a nucleic acid encoding the CD47/SIRPa interaction blocker with a size greater than 40 kDa. A pharmaceutical composition for immunotherapy of a PSMA-positive tumour, containing an effective amount of the modified NK cell and a pharmaceutically acceptable filler. A method for reducing the tumour mass in an individual with prostate cancer, including introduction of an effective amount of the NK cell to the individual. A method for increasing the survival of an individual with prostate cancer, including introduction of an effective amount of the NK cell to the individual.

EFFECT: invention provides a possibility of increasing the efficiency of using human CAR NK cells to eliminate cells of solid tumours and conduct therapy of neoplasms of various etiologies due to the expression of CD47/SIRPa interaction blockers.

12 cl, 12 dwg, 6 ex